Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases.

Biology

Croft PK, Chittoory H, Nguyen TH, Saunus JM, Kim WG, McCart Reed AE, Lim M, De Luca XM, Ferguson K, Niland C, Mazzieri R, Dolcetti R, Simpson PT, Lakhani SR.
PMID: 34064871
Biology (Basel). 2021 May 11;10(5). doi: 10.3390/biology10050425.

The heterogeneity of tumor infiltrating lymphocytes (TILs) is not well characterized in brain metastasis. To address this, we performed a targeted analysis of immune-cell subsets in brain metastasis tissues to test immunosuppressive routes involved in brain metastasis. We performed...

Cite
Croft PK, Chittoory H, Nguyen TH, et al. Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology (Basel). 2021;10(5)doi: 10.3390/biology10050425.
Croft, P. K., Chittoory, H., Nguyen, T. H., Saunus, J. M., Kim, W. G., McCart Reed, A. E., Lim, M., De Luca, X. M., Ferguson, K., Niland, C., Mazzieri, R., Dolcetti, R., Simpson, P. T., & Lakhani, S. R. (2021). Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology, 10(5), . https://doi.org/10.3390/biology10050425
Croft, Priyakshi Kalita-de, et al. "Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases." Biology vol. 10,5 (2021). doi: https://doi.org/10.3390/biology10050425
Croft PK, Chittoory H, Nguyen TH, Saunus JM, Kim WG, McCart Reed AE, Lim M, De Luca XM, Ferguson K, Niland C, Mazzieri R, Dolcetti R, Simpson PT, Lakhani SR. Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology (Basel). 2021 May 11;10(5). doi: 10.3390/biology10050425. PMID: 34064871; PMCID: PMC8150725.
Copy Download .nbib Format: NLM
Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases.

Biology

Croft PK, Chittoory H, Nguyen TH, Saunus JM, Kim WG, McCart Reed AE, Lim M, De Luca XM, Ferguson K, Niland C, Mazzieri R, Dolcetti R, Simpson PT, Lakhani SR.
PMID: 34064871
Biology (Basel). 2021 May 11;10(5). doi: 10.3390/biology10050425.

The heterogeneity of tumor infiltrating lymphocytes (TILs) is not well characterized in brain metastasis. To address this, we performed a targeted analysis of immune-cell subsets in brain metastasis tissues to test immunosuppressive routes involved in brain metastasis. We performed...

Cite
Croft PK, Chittoory H, Nguyen TH, et al. Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology (Basel). 2021;10(5)doi: 10.3390/biology10050425.
Croft, P. K., Chittoory, H., Nguyen, T. H., Saunus, J. M., Kim, W. G., McCart Reed, A. E., Lim, M., De Luca, X. M., Ferguson, K., Niland, C., Mazzieri, R., Dolcetti, R., Simpson, P. T., & Lakhani, S. R. (2021). Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology, 10(5), . https://doi.org/10.3390/biology10050425
Croft, Priyakshi Kalita-de, et al. "Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases." Biology vol. 10,5 (2021). doi: https://doi.org/10.3390/biology10050425
Croft PK, Chittoory H, Nguyen TH, Saunus JM, Kim WG, McCart Reed AE, Lim M, De Luca XM, Ferguson K, Niland C, Mazzieri R, Dolcetti R, Simpson PT, Lakhani SR. Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology (Basel). 2021 May 11;10(5). doi: 10.3390/biology10050425. PMID: 34064871; PMCID: PMC8150725.
Copy Download .nbib Format: NLM
A Molecular and Morphological Deep-Dive Into Metaplastic Breast Cancers.

Cancer informatics

McCart Reed AE, Lakhani SR.
PMID: 31205411
Cancer Inform. 2019 May 17;18:1176935119850155. doi: 10.1177/1176935119850155. eCollection 2019.

Metaplastic breast cancers (MBC) are relatively rare but account for significant global breast cancer mortality. Typically presenting without oestrogen and progesterone receptors or HER2 expression, these triple negative breast cancers are the archetypal 'stem cell-like' tumours that show a...

Cite
McCart Reed AE, Lakhani SR. A Molecular and Morphological Deep-Dive Into Metaplastic Breast Cancers. Cancer Inform. 2019;18:1176935119850155doi: 10.1177/1176935119850155.
McCart Reed, A. E., & Lakhani, S. R. (2019). A Molecular and Morphological Deep-Dive Into Metaplastic Breast Cancers. Cancer informatics, 181176935119850155. https://doi.org/10.1177/1176935119850155
McCart Reed, Amy E, and Lakhani, Sunil R. "A Molecular and Morphological Deep-Dive Into Metaplastic Breast Cancers." Cancer informatics vol. 18 (2019): 1176935119850155. doi: https://doi.org/10.1177/1176935119850155
McCart Reed AE, Lakhani SR. A Molecular and Morphological Deep-Dive Into Metaplastic Breast Cancers. Cancer Inform. 2019 May 17;18:1176935119850155. doi: 10.1177/1176935119850155. eCollection 2019. PMID: 31205411; PMCID: PMC6535896.
Copy Download .nbib Format: NLM
Using whole-genome sequencing data to derive the homologous recombination deficiency scores.

NPJ breast cancer

de Luca XM, Newell F, Kazakoff SH, Hartel G, McCart Reed AE, Holmes O, Xu Q, Wood S, Leonard C, Pearson JV, Lakhani SR, Waddell N, Nones K, Simpson PT.
PMID: 32818150
NPJ Breast Cancer. 2020 Aug 07;6:33. doi: 10.1038/s41523-020-0172-0. eCollection 2020.

The homologous recombination deficiency (HRD) score was developed using whole-genome copy number data derived from arrays as a way to infer deficiency in the homologous recombination DNA damage repair pathway (in particular

Cite
de Luca XM, Newell F, Kazakoff SH, et al. Using whole-genome sequencing data to derive the homologous recombination deficiency scores. NPJ Breast Cancer. 2020;6:33doi: 10.1038/s41523-020-0172-0.
de Luca, X. M., Newell, F., Kazakoff, S. H., Hartel, G., McCart Reed, A. E., Holmes, O., Xu, Q., Wood, S., Leonard, C., Pearson, J. V., Lakhani, S. R., Waddell, N., Nones, K., & Simpson, P. T. (2020). Using whole-genome sequencing data to derive the homologous recombination deficiency scores. NPJ breast cancer, 633. https://doi.org/10.1038/s41523-020-0172-0
de Luca, Xavier M, et al. "Using whole-genome sequencing data to derive the homologous recombination deficiency scores." NPJ breast cancer vol. 6 (2020): 33. doi: https://doi.org/10.1038/s41523-020-0172-0
de Luca XM, Newell F, Kazakoff SH, Hartel G, McCart Reed AE, Holmes O, Xu Q, Wood S, Leonard C, Pearson JV, Lakhani SR, Waddell N, Nones K, Simpson PT. Using whole-genome sequencing data to derive the homologous recombination deficiency scores. NPJ Breast Cancer. 2020 Aug 07;6:33. doi: 10.1038/s41523-020-0172-0. eCollection 2020. PMID: 32818150; PMCID: PMC7414867.
Copy Download .nbib Format: NLM
Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases.

Biology

Croft PK, Chittoory H, Nguyen TH, Saunus JM, Kim WG, McCart Reed AE, Lim M, De Luca XM, Ferguson K, Niland C, Mazzieri R, Dolcetti R, Simpson PT, Lakhani SR.
PMID: 34064871
Biology (Basel). 2021 May 11;10(5). doi: 10.3390/biology10050425.

The heterogeneity of tumor infiltrating lymphocytes (TILs) is not well characterized in brain metastasis. To address this, we performed a targeted analysis of immune-cell subsets in brain metastasis tissues to test immunosuppressive routes involved in brain metastasis. We performed...

Cite
Croft PK, Chittoory H, Nguyen TH, et al. Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology (Basel). 2021;10(5)doi: 10.3390/biology10050425.
Croft, P. K., Chittoory, H., Nguyen, T. H., Saunus, J. M., Kim, W. G., McCart Reed, A. E., Lim, M., De Luca, X. M., Ferguson, K., Niland, C., Mazzieri, R., Dolcetti, R., Simpson, P. T., & Lakhani, S. R. (2021). Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology, 10(5), . https://doi.org/10.3390/biology10050425
Croft, Priyakshi Kalita-de, et al. "Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases." Biology vol. 10,5 (2021). doi: https://doi.org/10.3390/biology10050425
Croft PK, Chittoory H, Nguyen TH, Saunus JM, Kim WG, McCart Reed AE, Lim M, De Luca XM, Ferguson K, Niland C, Mazzieri R, Dolcetti R, Simpson PT, Lakhani SR. Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology (Basel). 2021 May 11;10(5). doi: 10.3390/biology10050425. PMID: 34064871; PMCID: PMC8150725.
Copy Download .nbib Format: NLM
LobSig is a multigene predictor of outcome in invasive lobular carcinoma.

NPJ breast cancer

McCart Reed AE, Lal S, Kutasovic JR, Wockner L, Robertson A, de Luca XM, Kalita-de Croft P, Dalley AJ, Coorey CP, Kuo L, Ferguson K, Niland C, Miller G, Johnson J, Reid LE, Males R, Saunus JM, Chenevix-Trench G, Coin L, Lakhani SR, Simpson PT.
PMID: 31263747
NPJ Breast Cancer. 2019 Jun 27;5:18. doi: 10.1038/s41523-019-0113-y. eCollection 2019.

Invasive lobular carcinoma (ILC) is the most common special type of breast cancer, and is characterized by functional loss of E-cadherin, resulting in cellular adhesion defects. ILC typically present as estrogen receptor positive, grade 2 breast cancers, with a...

Cite
McCart Reed AE, Lal S, Kutasovic JR, et al. LobSig is a multigene predictor of outcome in invasive lobular carcinoma. NPJ Breast Cancer. 2019;5:18doi: 10.1038/s41523-019-0113-y.
McCart Reed, A. E., Lal, S., Kutasovic, J. R., Wockner, L., Robertson, A., de Luca, X. M., Kalita-de Croft, P., Dalley, A. J., Coorey, C. P., Kuo, L., Ferguson, K., Niland, C., Miller, G., Johnson, J., Reid, L. E., Males, R., Saunus, J. M., Chenevix-Trench, G., Coin, L., Lakhani, S. R., & Simpson, P. T. (2019). LobSig is a multigene predictor of outcome in invasive lobular carcinoma. NPJ breast cancer, 518. https://doi.org/10.1038/s41523-019-0113-y
McCart Reed, Amy E, et al. "LobSig is a multigene predictor of outcome in invasive lobular carcinoma." NPJ breast cancer vol. 5 (2019): 18. doi: https://doi.org/10.1038/s41523-019-0113-y
McCart Reed AE, Lal S, Kutasovic JR, Wockner L, Robertson A, de Luca XM, Kalita-de Croft P, Dalley AJ, Coorey CP, Kuo L, Ferguson K, Niland C, Miller G, Johnson J, Reid LE, Males R, Saunus JM, Chenevix-Trench G, Coin L, Lakhani SR, Simpson PT. LobSig is a multigene predictor of outcome in invasive lobular carcinoma. NPJ Breast Cancer. 2019 Jun 27;5:18. doi: 10.1038/s41523-019-0113-y. eCollection 2019. PMID: 31263747; PMCID: PMC6597578.
Copy Download .nbib Format: NLM
Clinicopathologic significance of nuclear HER4 and phospho-YAP(S.

Therapeutic advances in medical oncology

Kalita-de Croft P, Lim M, Chittoory H, de Luca XM, Kutasovic JR, Day BW, Al-Ejeh F, Simpson PT, McCart Reed AE, Lakhani SR, Saunus JM.
PMID: 33014146
Ther Adv Med Oncol. 2020 Jul 31;12:1758835920946259. doi: 10.1177/1758835920946259. eCollection 2020.

BACKGROUND: Human epidermal growth factor receptor-4 (HER4) and yes-associated protein-1 (YAP) are candidate therapeutic targets in oncology. YAP's transcriptional coactivation function is modulated by the HER4 intracellular domain (HER4-ICD) METHODS: We performed immuno-phenotypic profiling of pathway markers in a...

Cite
Kalita-de Croft P, Lim M, Chittoory H, et al. Clinicopathologic significance of nuclear HER4 and phospho-YAP(S. Ther Adv Med Oncol. 2020;12:1758835920946259doi: 10.1177/1758835920946259.
Kalita-de Croft, P., Lim, M., Chittoory, H., de Luca, X. M., Kutasovic, J. R., Day, B. W., Al-Ejeh, F., Simpson, P. T., McCart Reed, A. E., Lakhani, S. R., & Saunus, J. M. (2020). Clinicopathologic significance of nuclear HER4 and phospho-YAP(S. Therapeutic advances in medical oncology, 121758835920946259. https://doi.org/10.1177/1758835920946259
Kalita-de Croft, Priyakshi, et al. "Clinicopathologic significance of nuclear HER4 and phospho-YAP(S." Therapeutic advances in medical oncology vol. 12 (2020): 1758835920946259. doi: https://doi.org/10.1177/1758835920946259
Kalita-de Croft P, Lim M, Chittoory H, de Luca XM, Kutasovic JR, Day BW, Al-Ejeh F, Simpson PT, McCart Reed AE, Lakhani SR, Saunus JM. Clinicopathologic significance of nuclear HER4 and phospho-YAP(S. Ther Adv Med Oncol. 2020 Jul 31;12:1758835920946259. doi: 10.1177/1758835920946259. eCollection 2020. PMID: 33014146; PMCID: PMC7517995.
Copy Download .nbib Format: NLM
Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients.

Cancers

Visan KS, Lobb RJ, Wen SW, Bedo J, Lima LG, Krumeich S, Palma C, Ferguson K, Green B, Niland C, Cloonan N, Simpson PT, McCart Reed AE, Everitt SJ, MacManus MP, Hartel G, Salomon C, Lakhani SR, Fielding D, Möller A.
PMID: 35008424
Cancers (Basel). 2022 Jan 05;14(1). doi: 10.3390/cancers14010257.

With five-year survival rates as low as 3%, lung cancer is the most common cause of cancer-related mortality worldwide. The severity of the disease at presentation is accredited to the lack of early detection capacities, resulting in the reliance...

Cite
Visan KS, Lobb RJ, Wen SW, et al. Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients. Cancers (Basel). 2022;14(1)doi: 10.3390/cancers14010257.
Visan, K. S., Lobb, R. J., Wen, S. W., Bedo, J., Lima, L. G., Krumeich, S., Palma, C., Ferguson, K., Green, B., Niland, C., Cloonan, N., Simpson, P. T., McCart Reed, A. E., Everitt, S. J., MacManus, M. P., Hartel, G., Salomon, C., Lakhani, S. R., Fielding, D., & Möller, A. (2022). Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients. Cancers, 14(1), . https://doi.org/10.3390/cancers14010257
Visan, Kekoolani S, et al. "Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients." Cancers vol. 14,1 (2022). doi: https://doi.org/10.3390/cancers14010257
Visan KS, Lobb RJ, Wen SW, Bedo J, Lima LG, Krumeich S, Palma C, Ferguson K, Green B, Niland C, Cloonan N, Simpson PT, McCart Reed AE, Everitt SJ, MacManus MP, Hartel G, Salomon C, Lakhani SR, Fielding D, Möller A. Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients. Cancers (Basel). 2022 Jan 05;14(1). doi: 10.3390/cancers14010257. PMID: 35008424; PMCID: PMC8750562.
Copy Download .nbib Format: NLM
Corrigendum to "Molecular signatures in breast cancer" [Methods 131 (2017) 135-146].

Methods (San Diego, Calif.)

Lal S, McCart Reed AE, de Luca XM, Simpson PT.
PMID: 29398118
Methods. 2019 Jul 15;164:120. doi: 10.1016/j.ymeth.2018.01.007. Epub 2018 Feb 03.

No abstract available.

Cite
Lal S, McCart Reed AE, de Luca XM, et al. Corrigendum to "Molecular signatures in breast cancer" [Methods 131 (2017) 135-146]. Methods. 2018;164:120doi: 10.1016/j.ymeth.2018.01.007.
Lal, S., McCart Reed, A. E., de Luca, X. M., & Simpson, P. T. (2019). Corrigendum to "Molecular signatures in breast cancer" [Methods 131 (2017) 135-146]. Methods (San Diego, Calif.), 164120. https://doi.org/10.1016/j.ymeth.2018.01.007
Lal, Samir, et al. "Corrigendum to "Molecular signatures in breast cancer" [Methods 131 (2017) 135-146]." Methods (San Diego, Calif.) vol. 164 (2019): 120. doi: https://doi.org/10.1016/j.ymeth.2018.01.007
Lal S, McCart Reed AE, de Luca XM, Simpson PT. Corrigendum to "Molecular signatures in breast cancer" [Methods 131 (2017) 135-146]. Methods. 2019 Jul 15;164:120. doi: 10.1016/j.ymeth.2018.01.007. Epub 2018 Feb 03. PMID: 29398118.
Copy Download .nbib Format: NLM
Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer.

Cancers

Kutasovic JR, McCart Reed AE, Sokolova A, Lakhani SR, Simpson PT.
PMID: 32244556
Cancers (Basel). 2020 Mar 31;12(4). doi: 10.3390/cancers12040848.

No abstract available.

Cite
Kutasovic JR, McCart Reed AE, Sokolova A, et al. Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. Cancers (Basel). 2020;12(4)doi: 10.3390/cancers12040848.
Kutasovic, J. R., McCart Reed, A. E., Sokolova, A., Lakhani, S. R., & Simpson, P. T. (2020). Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. Cancers, 12(4), . https://doi.org/10.3390/cancers12040848
Kutasovic, Jamie R, et al. "Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer." Cancers vol. 12,4 (2020). doi: https://doi.org/10.3390/cancers12040848
Kutasovic JR, McCart Reed AE, Sokolova A, Lakhani SR, Simpson PT. Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. Cancers (Basel). 2020 Mar 31;12(4). doi: 10.3390/cancers12040848. PMID: 32244556; PMCID: PMC7226487.
Copy Download .nbib Format: NLM
Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development.

Cancers

Kondrashova O, Shamsani J, O'Mara TA, Newell F, McCart Reed AE, Lakhani SR, Kirk J, Pearson JV, Waddell N, Spurdle AB.
PMID: 33917078
Cancers (Basel). 2021 Apr 07;13(8). doi: 10.3390/cancers13081762.

Risk of endometrial cancer (EC) is increased ~2-fold for women with a family history of cancer, partly due to inherited pathogenic variants in mismatch repair (MMR) genes. We explored the role of additional genes as explanation for familial EC...

Cite
Kondrashova O, Shamsani J, O'Mara TA, et al. Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development. Cancers (Basel). 2021;13(8)doi: 10.3390/cancers13081762.
Kondrashova, O., Shamsani, J., O'Mara, T. A., Newell, F., McCart Reed, A. E., Lakhani, S. R., Kirk, J., Pearson, J. V., Waddell, N., & Spurdle, A. B. (2021). Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development. Cancers, 13(8), . https://doi.org/10.3390/cancers13081762
Kondrashova, Olga, et al. "Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development." Cancers vol. 13,8 (2021). doi: https://doi.org/10.3390/cancers13081762
Kondrashova O, Shamsani J, O'Mara TA, Newell F, McCart Reed AE, Lakhani SR, Kirk J, Pearson JV, Waddell N, Spurdle AB. Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development. Cancers (Basel). 2021 Apr 07;13(8). doi: 10.3390/cancers13081762. PMID: 33917078; PMCID: PMC8067736.
Copy Download .nbib Format: NLM
Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.

Breast cancer research : BCR

McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR.
PMID: 33413533
Breast Cancer Res. 2021 Jan 07;23(1):6. doi: 10.1186/s13058-020-01384-6.

Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types, accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E-cadherin function, which underpins their characteristic discohesive growth...

Cite
McCart Reed AE, Kalinowski L, Simpson PT, et al. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res. 2021;23(1):6doi: 10.1186/s13058-020-01384-6.
McCart Reed, A. E., Kalinowski, L., Simpson, P. T., & Lakhani, S. R. (2021). Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast cancer research : BCR, 23(1), 6. https://doi.org/10.1186/s13058-020-01384-6
McCart Reed, Amy E, et al. "Invasive lobular carcinoma of the breast: the increasing importance of this special subtype." Breast cancer research : BCR vol. 23,1 (2021): 6. doi: https://doi.org/10.1186/s13058-020-01384-6
McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res. 2021 Jan 07;23(1):6. doi: 10.1186/s13058-020-01384-6. PMID: 33413533; PMCID: PMC7792208.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries